168 related articles for article (PubMed ID: 24403012)
1. The structure of Plasmodium yoelii merozoite surface protein 119, antibody specificity and implications for malaria vaccine design.
Curd RD; Birdsall B; Kadekoppala M; Ogun SA; Kelly G; Holder AA
Open Biol; 2014 Jan; 4(1):130091. PubMed ID: 24403012
[TBL] [Abstract][Full Text] [Related]
2. Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains.
Somner EA; Ogun SA; Sinha KA; Spencer Valero LM; Lee JJ; Harrison JA; Holder AA; Hormaeche CE; Khan ACM
Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():221-229. PubMed ID: 10206702
[TBL] [Abstract][Full Text] [Related]
3. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii.
Tian JH; Kumar S; Kaslow DC; Miller LH
Infect Immun; 1997 Aug; 65(8):3032-6. PubMed ID: 9234750
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.
Kedzierski L; Black CG; Stowers AW; Goschnick MW; Kaslow DC; Coppel RL
Vaccine; 2001 Sep; 19(32):4661-8. PubMed ID: 11535314
[TBL] [Abstract][Full Text] [Related]
5. Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region.
Ahlborg N; Ling IT; Howard W; Holder AA; Riley EM
Infect Immun; 2002 Feb; 70(2):820-5. PubMed ID: 11796616
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
Matsumoto S; Yukitake H; Kanbara H; Yamada T
J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
[TBL] [Abstract][Full Text] [Related]
7. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.
Goschnick MW; Black CG; Kedzierski L; Holder AA; Coppel RL
Infect Immun; 2004 Oct; 72(10):5840-9. PubMed ID: 15385485
[TBL] [Abstract][Full Text] [Related]
8. Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii.
Kawabata Y; Udono H; Honma K; Ueda M; Mukae H; Kadota J; Kohno S; Yui K
Infect Immun; 2002 Nov; 70(11):6075-82. PubMed ID: 12379684
[TBL] [Abstract][Full Text] [Related]
9. Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination.
Stanisic DI; Martin LB; Liu XQ; Jackson D; Cooper J; Good MF
Infect Immun; 2003 Oct; 71(10):5700-13. PubMed ID: 14500491
[TBL] [Abstract][Full Text] [Related]
10. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.
Yoshida S; Nagumo H; Yokomine T; Araki H; Suzuki A; Matsuoka H
PLoS One; 2010 Oct; 5(10):e13727. PubMed ID: 21060850
[TBL] [Abstract][Full Text] [Related]
11. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
Shi Q; Lynch MM; Romero M; Burns JM
Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
[TBL] [Abstract][Full Text] [Related]
12. Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response.
Hensmann M; Li C; Moss C; Lindo V; Greer F; Watts C; Ogun SA; Holder AA; Langhorne J
Eur J Immunol; 2004 Mar; 34(3):639-648. PubMed ID: 14991593
[TBL] [Abstract][Full Text] [Related]
13. Antigenic and sequence diversity at the C-terminus of the merozoite surface protein-1 from rodent malaria isolates, and the binding of protective monoclonal antibodies.
Benjamin PA; Ling IT; Clottey G; Valero LM; Ogun SA; Fleck SL; Walliker D; Morgan WD; Birdsall B; Feeney J; Holder AA
Mol Biochem Parasitol; 1999 Nov; 104(2):147-56. PubMed ID: 10593171
[TBL] [Abstract][Full Text] [Related]
14. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19).
Ahlborg N; Ling IT; Holder AA; Riley EM
Infect Immun; 2000 Apr; 68(4):2102-9. PubMed ID: 10722607
[TBL] [Abstract][Full Text] [Related]
15. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
Alaro JR; Lynch MM; Burns JM
Vaccine; 2010 Oct; 28(42):6876-84. PubMed ID: 20709001
[TBL] [Abstract][Full Text] [Related]
16. Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.
Okafor CM; Anumudu CI; Omosun YO; Uthaipibull C; Ayede I; Awobode HO; Odaibo AB; Langhorne J; Holder AA; Nwuba RI; Troye-Blomberg M
Malar J; 2009 Nov; 8():263. PubMed ID: 19930613
[TBL] [Abstract][Full Text] [Related]
17. Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice.
Sakai T; Hisaeda H; Nakano Y; Zhang M; Takashima M; Ishii K; Maekawa Y; Matsumoto S; Nitta Y; Miyazaki Ji; Yamamoto S; Himeno K
Vaccine; 2003 Mar; 21(13-14):1432-44. PubMed ID: 12615440
[TBL] [Abstract][Full Text] [Related]
18. Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii.
Eslava I; Payares G; Pernia BM; Holder AA; Spencer LM
Malar J; 2010 Feb; 9():46. PubMed ID: 20146804
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.
Kedzierski L; Black CG; Goschnick MW; Stowers AW; Coppel RL
Infect Immun; 2002 Dec; 70(12):6606-13. PubMed ID: 12438332
[TBL] [Abstract][Full Text] [Related]
20. A hybrid multistage protein vaccine induces protective immunity against murine malaria.
Singh B; Cabrera-Mora M; Jiang J; Moreno A
Infect Immun; 2012 Apr; 80(4):1491-501. PubMed ID: 22252877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
